Participant flow

Efficacy and Safety of Tisagenlecleucel in Adult Patients With Refractory or Relapsed Follicular Lymphoma · Source last updated 2026-07-09

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

groups

1. description

   All participants who were enrolled in the study

   id

   FG000

   title

   CTL019

periods

1. drop Withdraws

   1. reasons

      1. group Id

         FG000

         num Subjects

         1

      type

      Adverse Event

   2. reasons

      1. group Id

         FG000

         num Subjects

         7

      type

      Physician Decision

   3. reasons

      1. group Id

         FG000

         num Subjects

         7

      type

      Patient decision

   4. reasons

      1. group Id

         FG000

         num Subjects

         3

      type

      Lost to Follow-up

   5. reasons

      1. group Id

         FG000

         num Subjects

         22

      type

      Death

   milestones

   1. achievements

      1. group Id

         FG000

         num Subjects

         98

      comment

      Started = enrolled and entered pre-treatment phase

      type

      STARTED

   2. achievements

      1. group Id

         FG000

         num Subjects

         97

      comment

      Treated = infused with tisagenlecleucel

      type

      Treated

   3. achievements

      1. group Id

         FG000

         num Subjects

         1

      type

      Discontinued prior to infusion with tisagenlecleucel

   4. achievements

      1. group Id

         FG000

         num Subjects

         58

      comment

      Completed = Ongoing/in follow-up

      type

      COMPLETED

   5. achievements

      1. group Id

         FG000

         num Subjects

         40

      type

      NOT COMPLETED

   title

   Overall Study

pre Assignment Details

During the Screening phase and prior to enrolment into the study, participants' white blood cells were collected via leukapheresis.

recruitment Details

90 participants were planned, 98 patients were enrolled and 97 participants were infused with tisagenlecleucel.

Download exact source JSON → · Snapshot ctgov-results-191f4516d4760045304b24a0

Preserved source evidence · Not medical advice